In the U.S., $3 trillion is spent annually on healthcare with an estimated $1 trillion wasted. The shift in volume to value is an opportunity to align cost-effective medications and care to optimize patient outcomes.
As the U.S. healthcare industry continues to improve outcomes and access to care, innovative value-based agreements must be considered as a meaningful approach to address the unmet health needs of Americans and our healthcare system.
Innovative value-based agreements represent an important step toward a healthcare system centered on improved patient outcomes and reduced medical spending. Value-based agreements are driving this shift beyond transactional care to a system where payers, health systems and doctors are incentivized by value of care and patient outcomes, not volume of care provided.
Boehringer Ingelheim, a leader in value-based care, has worked with national and regional payers to develop best-in-class value-based agreements designed to more closely link the value of our treatments, across multiple chronic care categories, to improve patient medical outcomes and/or reduce cost trends associated with using these important medicines.
In our view and experience, value-based agreements are part of a solution that allows greater flexibility in how payers and biopharmaceutical companies can collaborate to support the shift to a value-based healthcare system.